Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2017 01/13/2017 01/17/2017 01/18/2017 01/19/2017 Date
41.84(c) 41.6(c) 38.22(c) 38.51(c) 39.08(c) Last
660 122 1 030 720 1 398 902 1 187 252 1 569 479 Volume
+1.43% -0.57% -8.13% +0.76% +1.48% Change
More quotes
Financials ($)
Sales 2016 41,3 M
EBIT 2016 -429 M
Net income 2016 -406 M
Finance 2016 581 M
Yield 2016 -
Sales 2017 49,0 M
EBIT 2017 -455 M
Net income 2017 -450 M
Finance 2017 554 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 65,9x
EV / Sales2017 56,2x
Capitalization 3 305 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
01/12 ALNYLAM PHARMACEUTICALS : Announces Management Change and Key Promotion
01/11 WEDNESDAY SECTOR LAGGARDS : Drugs, Biotechnology Stocks
01/04 ALNYLAM PHARMACEUTICALS, INC. (NASDA : ALNY) Files An 8-K Departure of Directors..
01/03 ALNYLAM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
01/03 ALNYLAM PHARMACEUTICALS : Announces Management Change and Key Promotion
01/03 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 35th Annual J.P. Morgan Hea..
2016 ALNYLAM PHARMACEUTICALS : Presents Initial 2017 Pipeline Goals at R&D Day with F..
2016 ALNYLAM PHARMACEUTICALS : to Webcast R&D Day
2016 ALNYLAM PHARMACEUTICALS : Patent Issued for Compositions and Methods for Inhibit..
2016 ALNYLAM PHARMACEUTICALS : Presents Updated Results from Phase 1/2 Study of ALN-C..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/17Dollar Plunges, Commodities Soar, Greatness Awaits - Trading with The Fly $u..
2
01/12Alnylam Pharmaceuticals upgraded by Vetr Inc. to strong-buy. $47.90 PT.  
01/11Alnylam shrugs off revusiran setback as follow-up heads for Ph III read-out: ..
1
01/11Alnylam Pharmaceuticals downgraded by Vetr Inc. to hold. $46.27 PT.  
01/10Want the latest upgrades & downgrades for $NOVN $ORA $ALNY $SNTS $HPT? Ch.. 
More tweets
Qtime:44
News from SeekingAlpha
01/06 Select Small Caps Stand Out Amid Wider 2016 Stock Market Declines
01/06 New operating chief at Neurocrine; shares up 5% premarket
01/03 Alnylam business chief bids adieu
01/03 The Best 29 Stocks For 2017
2016 After Hours Gainers / Losers
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 63,4 $
Spread / Average Target 65%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John M. Maraganore Chief Executive Officer & Director
Barry E. Greene President
Michael W. Bonney Chairman
Yvonne Greenstreet Chief Operating Officer & Executive Vice President
Michael P. Mason Treasurer, Chief Financial & Accounting Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICAL..2.86%3 305
INCYTE CORPORATION14.78%21 681
QUINTILES IMS HOLDINGS..-0.60%18 609
CELLTRION, INC.--.--%10 542
LONZA GROUP AG4.14%9 661
ALKERMES PLC0.45%8 485
More Results